Ishima Y[au] - Search Results

Year	Number of Results
1968	1
1975	2
1978	1
1981	1
1982	2
1984	2
1993	1
1996	2
1997	1
1999	1
2000	1
2001	1
2002	1
2005	3
2006	1
2007	2
2008	1
2009	2
2010	6
2011	3
2012	7
2013	9
2014	13
2015	8
2016	7
2017	13
2018	14
2019	10
2020	17
2021	14
2022	16
2023	1

1

Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction.

Enoki Y, Watanabe H, Arake R, Fujimura R, Ishiodori K, Imafuku T, Nishida K, Sugimoto R, Nagao S, Miyamura S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T. Enoki Y, et al. Among authors: ishima y. J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):735-747. doi: 10.1002/jcsm.12202. Epub 2017 Jun 12. J Cachexia Sarcopenia Muscle. 2017. PMID: 28608457 Free PMC article.

2

The Challenge to Deliver Oxaliplatin (l-OHP) to Solid Tumors: Development of Liposomal l-OHP Formulations.

Matsuo NCA, Ando H, Doi Y, Shimizu T, Ishima Y, Ishida T. Matsuo NCA, et al. Among authors: ishima y. Chem Pharm Bull (Tokyo). 2022;70(5):351-358. doi: 10.1248/cpb.c22-00099. Chem Pharm Bull (Tokyo). 2022. PMID: 35491191 Free article. Review.

3

The New Delivery Strategy of Albumin Carrier Utilizing the Interaction with Albumin Receptors.

Ishima Y, Maruyama T, Otagiri M, Chuang VTG, Ishida T. Ishima Y, et al. Chem Pharm Bull (Tokyo). 2022;70(5):330-333. doi: 10.1248/cpb.c21-01024. Chem Pharm Bull (Tokyo). 2022. PMID: 35491188 Free article. Review.

4

Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products.

Ibrahim M, Ramadan E, Elsadek NE, Emam SE, Shimizu T, Ando H, Ishima Y, Elgarhy OH, Sarhan HA, Hussein AK, Ishida T. Ibrahim M, et al. Among authors: ishima y. J Control Release. 2022 Nov;351:215-230. doi: 10.1016/j.jconrel.2022.09.031. Epub 2022 Sep 22. J Control Release. 2022. PMID: 36165835 Review.

5

[Human Serum Albumin as Carrier in Drug Delivery Systems].

Ishima Y, Maruyama T. Ishima Y, et al. Yakugaku Zasshi. 2016;136(1):39-47. doi: 10.1248/yakushi.15-00227-1. Yakugaku Zasshi. 2016. PMID: 26725666 Free article. Review. Japanese.

6

Using Bio-Layer Interferometry to Evaluate Anti-PEG Antibody-Mediated Complement Activation.

Mostafa M, Elsadek NE, Emam SE, Ando H, Shimizu T, Abdelkader H, Ishima Y, Aly UF, Sarhan HA, Ishida T. Mostafa M, et al. Among authors: ishima y. Biol Pharm Bull. 2022;45(1):129-135. doi: 10.1248/bpb.b21-00772. Biol Pharm Bull. 2022. PMID: 34980774 Free article.

7

[The Charm of Protein for Drug Development].

Ishima Y, Taguchi K. Ishima Y, et al. Yakugaku Zasshi. 2020;140(2):139-140. doi: 10.1248/yakushi.19-00187-F. Yakugaku Zasshi. 2020. PMID: 32009034 Free article. Japanese. No abstract available.

8

Development of an Antigen Delivery System for a B Cell-Targeted Vaccine as an Alternative to Dendritic Cell-Targeted Vaccines.

Shimizu T, Kawaguchi Y, Ando H, Ishima Y, Ishida T. Shimizu T, et al. Among authors: ishima y. Chem Pharm Bull (Tokyo). 2022;70(5):341-350. doi: 10.1248/cpb.c22-00047. Chem Pharm Bull (Tokyo). 2022. PMID: 35491190 Free article. Review.

9

Albumin-Based Nitric Oxide Traffic System for the Treatment of Intractable Cancers.

Ishima Y. Ishima Y. Biol Pharm Bull. 2017;40(2):128-134. doi: 10.1248/bpb.b16-00867. Biol Pharm Bull. 2017. PMID: 28154250 Free article. Review.

10

Drug Delivery System for Refractory Cancer Therapy via an Endogenous Albumin Transport System.

Ishima Y, Maruyama T, Otagiri M, Ishida T. Ishima Y, et al. Chem Pharm Bull (Tokyo). 2020;68(7):583-588. doi: 10.1248/cpb.c20-00026. Chem Pharm Bull (Tokyo). 2020. PMID: 32611995 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results